FHTX
Foghorn Therapeutics Inc
2.00$
-1.5%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 150.2% | 14.8% | 16.5% | 11.6% | 9.0% | 26.6% | – | 11.9% | 245.3% | 8.7% | 7.3% | – | – | |
| -50.2% | 85.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 88.1% | -145.3% | 91.3% | 92.7% | 100.0% | 42.7% | |
| 150.2% | 404.8% | 505.6% | 345.5% | 316.2% | 718.1% | 363.3% | 276.5% | 245.3% | 248.1% | 558.9% | 115.3% | 217.0% | |
| 47.5% | 121.7% | 152.7% | 106.3% | 89.3% | 222.4% | 121.6% | 90.8% | 81.6% | 73.5% | 201.4% | 39.5% | 71.8% | |
| 47.5% | 526.5% | 658.3% | 486.6% | 405.5% | 940.5% | 485.0% | 367.3% | 81.6% | 303.2% | 753.0% | 154.8% | 229.1% | |
| -97.7% | -441.3% | -558.3% | -386.6% | -305.5% | -840.5% | -385.0% | -279.2% | -226.9% | -211.9% | -660.3% | -54.8% | -186.4% | |
| – | 39.3% | – | – | – | – | – | – | – | – | – | – | – | |
| -77.9% | -383.4% | -495.4% | -333.6% | -244.9% | -682.9% | -316.4% | -237.3% | -194.4% | -234.3% | -608.4% | -44.7% | -175.8% | |
| 4.2% | 34.4% | 15.7% | – | -9.0% | -27.7% | – | – | – | – | – | – | – | |
| -82.1% | -417.9% | -495.4% | -333.6% | -244.9% | -682.9% | -316.4% | -237.3% | -194.4% | -234.3% | -608.4% | -44.7% | -175.8% | |
| -72.9% | -368.7% | -478.8% | -340.3% | -235.5% | -656.2% | -302.5% | -225.4% | -183.9% | -225.6% | -601.1% | -43.5% | -170.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.